News
IMMP
2.510
+8.19%
0.190
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 1h ago
IMMUTEP ANNOUNCES POSITIVE PRELIMINARY TOPLINE RESULTS FROM TACTI-003 COHORT B
Reuters · 1h ago
IMMUTEP LTD: EXPECTS TO REPORT PRIMARY ENDPOINT FROM COHORTS A & B IN H1 CY2024
Reuters · 1h ago
Immutep Announced Tuesday, Data From Efti In Combination With Keytruda In First Line Head And Neck Squamous Cell Carcinoma Patients Who Do Not Express PD-L1 Shows A Preliminary 26.9% Response Rate, The Primary Endpoint Of The Study
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease. Preliminary topline results from the TACTI-003 Phase IIb trial of eftilagimod alpha in combination with KEYTRUDA.
Benzinga · 3h ago
BUZZ-Biotech firm Immutep jumps on positive study results for cancer therapy
Biotech firm Immutep jumps on positive study results for cancer therapy. Shares of Australian biotechnology firm rise as much as 11.7% to highest level since March 24, 2022. Second-biggest gainer in the ASX All Ordinaries index.
Reuters · 10h ago
Wilsons Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
TipRanks · 1d ago
Weekly Report: what happened at IMMP last week (0415-0419)?
Weekly Report · 2d ago
Immutep: Report of foreign issuer
Press release · 4d ago
Immutep Advances Novel Autoimmune Therapy with Phase I Trial
TipRanks · 5d ago
Immutep Appoints Leading Research Institute To Conduct First-in-Human Phase I Study Of IMP761
Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseases. Trial expected to begin mid-CY2024.
Benzinga · 6d ago
IMMUTEP RECEIVES POSITIVE FEEDBACK FROM THE SPANISH MEDICINES AGENCY FOR UPCOMING TACTI-004 REGISTRATIONAL TRIAL IN METASTATIC NON-SMALL CELL LUNG CANCER
Reuters · 04/17 12:00
Immutep Announced Tuesday, Positive Feedback From Spanish Medicines Agency For Upcoming TACTI-004 Registrational Trial In Metastatic Non-Small Cell Lung Cancer
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease. The company has received positive feedback from the Spanish Agency for Medicines and Health Products. The Company is developing a lung cancer trial for the treatment of lung cancer.
Benzinga · 04/17 09:20
Weekly Report: what happened at IMMP last week (0408-0412)?
Weekly Report · 04/15 10:15
Weekly Report: what happened at IMMP last week (0401-0405)?
Weekly Report · 04/08 10:18
Immutep Ltd (PRRUF) Gets a Buy from Bell Potter
TipRanks · 04/05 00:07
Weekly Report: what happened at IMMP last week (0325-0329)?
Weekly Report · 04/01 10:17
Weekly Report: what happened at IMMP last week (0318-0322)?
Weekly Report · 03/25 10:19
Weekly Report: what happened at IMMP last week (0311-0315)?
Weekly Report · 03/18 10:17
Weekly Report: what happened at IMMP last week (0304-0308)?
Weekly Report · 03/11 10:16
Analyst Issues Buy Rating on Immutep Stock Amid Promising Efti Drug Trial Results
TipRanks · 03/07 05:00
More
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.